NewsRoom Articles - Page 76 of 154 - PsychedelicNewsWire (PNW)

FridayDec 10, 2021 2:00 pm

DEA Again Bumps Up 2022 Production Quotas for Psychedelics

In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances, such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota once again for these psychedelic substances, in response to the increased demand and interest in the scientific community. When it first released its quota for the year, psilocybin’s production quota was 30 grams. This number has now grown to 8,000 grams, which is more than a 26,000% increase. In its statement, the DEA stated that the aggregate production…

FridayDec 10, 2021 9:32 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

ThursdayDec 09, 2021 1:36 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:25 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…

ThursdayDec 09, 2021 9:25 am

Ongoing Psychedelics Research Could Yield Novel Treatments for Mental Disorders

Data from the National Alliance of Mental Health suggests that one in five adults will suffer from a mental health condition in their lifetime. Traditional treatments cause various side effects and can take time to work, which has prompted researchers to seek alternative treatment options for these conditions. Chang Lu, a researcher from Virginia Tech, has been conducting research on psychedelics that could be used in the treatment of different mental health conditions. Lu, who is a Fred W. Bull Professor of Chemical Engineering, is using a process developed in his laboratory to help collaborators at Virginia Commonwealth University carry…

WednesdayDec 08, 2021 3:30 pm

Research Finds That Psychedelics Users Were Less Stressed During COVID-19 Lockdowns

Research has found that the coronavirus lockdowns affected the psychological stress of individuals, which in turn caused increases in depression and anxiety across the globe. Figures from the U.S. Census Bureau show that last December, more than 40% of individuals reported symptoms of depression or anxiety. This figure is almost four times the percentage reported in December 2019. Given the potential of psychedelics to treat anxiety, depression and post-traumatic stress disorder, researchers sought to find out whether the use of these substances had impacted mental health in the period between April and July 2020. For their study, the researchers gathered…

TuesdayDec 07, 2021 2:15 pm

Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

Atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improving the lives of patients with mental health disorders. Atai, which is already the biggest shareholder of Compass Pathways, purchased more than 619,000 additional shares in Compass Pathways, increasing its stake in the company to 20.8%. The Peter Thiel-backed biopharmaceutical start-up bought each share at roughly $31 and paid a total of about $12 million. A source close to…

TuesdayDec 07, 2021 11:13 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year

2021 marked Mydecine’s patent application for its MYCO-003 drug candidate It also marked notable clinical trials on various aspects, including smoking cessation Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics These milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), since its inception in 2020, has been aiming to transform the treatment of mental health disorders and addiction through biotechnology. The company…

MondayDec 06, 2021 3:45 pm

UBC Study Shows Psychedelic Drug Microdoses Show Promise Against Mental Illnesses

Psychedelic substances have been used for centuries among the pre-Columbian Aztec and Mayan societies as well as indigenous peoples of the Americas, which include the Huichol and the Mazatec. The use of smaller doses of psychedelics in societies such as the Mazatec people to support the healing of various physical conditions is common despite scanty documentation on it. Microdosing refers to the practice of consuming small doses of a psychedelic substance to benefit from it while minimizing the drug’s undesirable side effects. For years, researchers have conducted studies on psychedelic microdosing in order to learn its benefits, with a recent…

MondayDec 06, 2021 10:47 am

FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards The company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug process The FDA has notified the company that its review of the IND for using TRP-8802 to treat fibromyalgia is complete and a trial planned in conjunction with the University of Michigan may proceed to patient…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000